Where Will Neurocrine Biosciences Be in 5 Years?

Neurocrine Biosciences generated $959 million in Q2 2026 revenue with 39% year-over-year growth. The company's flagship drug Ingrezza continues strong double-digit growth, while newer treatments Crenessity and Vykat XR are expanding rapidly. With late-stage clinical trials for depression and schizophrenia treatments expected in 2027, analysts project the company could reach $6-7 billion in annual revenue by 2031, though success depends on pipeline candidates and managing pricing pressures.

10/25/2026, 6:45 AM • The Motley Fool

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

10/19/2026, 1:00 PM • GlobeNewswire

Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGR

The global brain health supplements market is projected to grow from USD 12.47 billion in 2025 to USD 35.41 billion by 2035, driven by increasing consumer awareness of cognitive wellness, demand for natural ingredients, and e-commerce expansion. North America leads with 43.1% market share, while memory enhancement remains the top application. Key growth factors include aging populations, younger consumers seeking cognitive support, and clinical validation of natural ingredients like Bacopa monnieri and Ginkgo Biloba.

10/16/2026, 4:57 AM • GlobeNewswire

Teva to Host R&D Day on Wednesday, November 11 in New York City

Teva Pharmaceutical Industries announced it will host an R&D Day on November 11, 2026, in New York to discuss its R&D pipeline and transformation strategy into an innovative biopharma company. The company also announced FDA approval of WELTRUZA™ (olanzapine), the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia.

10/12/2026, 5:45 PM • GlobeNewswire

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Teva Pharmaceutical has surged 110% in the last year, hitting a 52-week high of $40.79 per share, driven by its pivot from generic to branded drugs. The company's innovative portfolio of three branded products is projected to generate $3.7 billion in 2026 revenue, while net debt has decreased from $18.4 billion (end of 2022) to $12.9 billion, earning a credit rating upgrade to investment-grade status. With peak annual sales of $10 billion anticipated from its late-stage pipeline and earnings expected to grow 40.7% between 2026-2027, analysts view the stock as undervalued at 12.9x forward earnings.

09/29/2026, 5:35 AM • The Motley Fool

Teva Releases Q3 2026 Aide Memoire

Teva Pharmaceutical Industries Ltd. announced the availability of its Q3 2026 Aide Memoire document to assist investors ahead of third quarter 2026 results, scheduled for release on November 3, 2026, followed by a conference call at 8:00 a.m. ET. The company is transforming into a leading innovative biopharmaceutical company supported by its generics business.

09/23/2026, 4:45 PM • GlobeNewswire

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Teva Pharmaceutical Industries announced it will release its Q3 2026 financial results on November 3, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. The company is executing its Pivot to Growth strategy focused on expanding its innovative and biosimilar medicines pipeline while maintaining its generics business.

09/23/2026, 4:45 PM • GlobeNewswire

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Teva released findings from a discrete choice experiment showing that healthcare providers prioritize somnolence risk, long-term efficacy data, and drug-drug interaction profiles when selecting treatments for tardive dyskinesia in patients aged 55+. AUSTEDO (deutetrabenazine) was found to align most closely with these preferred attributes across all patient profiles. Additionally, data from the IMPACT-TD Registry showed that untreated tardive dyskinesia persists in 89-96% of patients over 24 months with no spontaneous resolution, underscoring the need for proactive treatment.

09/18/2026, 4:32 PM • GlobeNewswire

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Teva announced real-world data demonstrating that UZEDY (risperidone) extended-release injectable suspension shows superior treatment continuity compared to other long-acting injectables in schizophrenia patients and oral antipsychotics in bipolar I disorder. The data revealed UZEDY reduced emergency room visits and hospitalizations, delivering over $1,000 per patient per month in direct cost savings and 40% lower emergency department visit rates versus paliperidone palmitate once-monthly.

09/18/2026, 4:31 PM • GlobeNewswire

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Teva presented post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting injectable olanzapine formulation for schizophrenia treatment. Results showed over 56% of participants achieved stabilization, 21% achieved remission after 6+ months, and only 4% of stabilized patients relapsed. Data also demonstrated feasible switching strategies from oral or short-acting olanzapine formulations while maintaining therapeutic ranges. FDA approval is anticipated in Q4 2026.

09/18/2026, 4:30 PM • GlobeNewswire

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

09/07/2026, 1:00 PM • GlobeNewswire

Teva Announces Launch of Offering of Senior Notes

Teva Pharmaceutical announced its intention to issue EUR and USD-denominated senior notes through special purpose finance subsidiaries. The company plans to use net proceeds to redeem certain existing notes, including 6.750% notes due 2028, 7.875% and 7.375% sustainability-linked notes due 2029, and portions of 4.750% and 4.375% notes. The offering is subject to market conditions and is not conditioned on the redemptions.

09/07/2026, 3:53 AM • GlobeNewswire

Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The multiple system atrophy (MSA) clinical trial pipeline is experiencing significant momentum with 22+ companies developing 24+ pipeline drugs. The pipeline is diversifying beyond traditional approaches to include oral small molecules, cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors. Recent developments include Alterity Therapeutics achieving FDA alignment on Phase III for ATH434, Teva receiving Fast Track designation for TEV-56286, and iRegene Therapeutics enrolling the first patient in a randomized controlled trial for NouvNeu004 in China.

08/26/2026, 1:00 PM • GlobeNewswire

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Michael R. Hayden, a director at Ionis Pharmaceuticals, purchased 20,000 shares worth $1.1 million on July 30-31, 2026, increasing his total holdings by 34%. The insider purchase signals confidence in the company's RNA-targeted therapy pipeline, which includes recently approved drugs like Tryngolza and upcoming treatments for Alexander disease and Angelman syndrome. Despite current net losses of $564.8 million, the company maintains $873.8 million in trailing twelve-month revenue and an $8.8 billion market valuation.

08/03/2026, 3:17 PM • The Motley Fool

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors due to its more attractive valuation ratios and strong drug pipeline expected to drive growth in 2027.

07/09/2026, 12:12 PM • The Motley Fool